#long-acting injectables

ViiV Cabenuva injectable cabotegravir rilpivirine

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

The Freedom to Be

Switching HIV regimens from a daily oral pill to a monthly injectable has given Alex Vance more headspace.

Monthly Injectable Cabenuva Approved

Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.

My First CROI

I just attended my first CROI (Conference on Retroviruses and Opportunistic Infections). It was also my first virtual conference...

More Women…Please?

The week of March 6 – March 10, 2021 I had the privilege of attending the Conference on Retroviruses and Opportunistic Infections (CROI).

Cabenuva

Prevention: PrEP for Women

A study finds that long-acting cabotegravir is an effective PrEP option for women.

Long-Acting Cabotegravir Is an Effective PrEP Option for Women

Cabotegravir injections and daily Truvada are both highly effective, but some people may find it easier to use the long-acting regimen.

POZ Poll: Which type of HIV treatment do you prefer: daily pills or monthly injections?

Not All Women Are On Board With Injectable HIV Meds

Whether for treatment or prevention, women’s interest in injectable antiretrovirals varied based on their relationship with injection.

More Good News About Injectable Treatment

A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.

2020 Top HIV Treatment Stories

COVID-19, HIV vaccines, cure news and long-acting injectables stood out among the top HIV treatment stories of the year.

Long-Acting Injectable HIV Regimen Approved in Europe

The European Medicines Agency gave the green light to injectable cabotegravir and rilpivirine for HIV treatment.

Providers Can Successfully Administer Monthly Injectable HIV Treatment

A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.

For Women, Injectable Cabotegravir Is More Effective Than Truvada as PrEP

Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.

People Prefer Injectable Cabenuva After Switching From Oral Meds

After years of taking daily oral cabotegravir and Edurant, people with suppressed HIV switched to long-acting injectable Cabenuva.

Long-Acting Injectable Cabenuva May Not Require Oral Lead-In

A study found no difference in outcomes based on whether participants took oral meds for a month before switching to injectables.

#long-acting injectables

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

The Freedom to Be

Monthly Injectable Cabenuva Approved

My First CROI

More Women…Please?

Cabenuva

Prevention: PrEP for Women

Long-Acting Cabotegravir Is an Effective PrEP Option for Women

POZ Poll: Which type of HIV treatment do you prefer: daily pills or monthly injections?

Not All Women Are On Board With Injectable HIV Meds

More Good News About Injectable Treatment

2020 Top HIV Treatment Stories

Long-Acting Injectable HIV Regimen Approved in Europe

Providers Can Successfully Administer Monthly Injectable HIV Treatment

For Women, Injectable Cabotegravir Is More Effective Than Truvada as PrEP

People Prefer Injectable Cabenuva After Switching From Oral Meds

Long-Acting Injectable Cabenuva May Not Require Oral Lead-In

Science News

Ask POZ